These findings from the LUX-Lung 7 study provide further support that tolerability-guided dose adjustment of afatinib reduces the incidence and severity of treatment-related AEs without affecting the efficacy or diminishing the effects of afatinib on PROs in patients with advanced EGFR mutation-positive NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.